The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...